4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Lyell Immunopharma, Inc. (LYEL) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 161 employees. Its market capitalization is roughly $311 million. In the fiscal year ended 2025-12-31, LYEL reported $0M in revenue and ($274M) in net income.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Interactive charts & full statements → Open the LYEL valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $85M |
| Operating Income (EBIT) | ($202M) | ($220M) | ($247M) | ($187M) |
| Net Income | ($274M) | ($343M) | ($235M) | ($183M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($44M) | ($61M) | ($37M) | ($46M) | ($57M) | — |
| Net Income | ($24M) | ($141M) | ($39M) | ($43M) | ($52M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $340M | $491M | $750M | $938M | — |
| Total Liabilities | $92M | $108M | $95M | $104M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LYEL viewer.
About TickerBase · Data methodology & sources